

"Discovering The World Of Chemistry"



Chancen zur Beteiligung im Kienne und immere Unternehmen (KMU)

Dr. Dimitrios Tzalis

Nationale Informationsveranstaltung zur IMI 2,

10th July 2014 Frankfurt





Taros: Stability, Capability, Flexibility


as a leader in drug discovery, Taros provides contract discovery, development, and manufacturing services to serve our clients' needs

- Founded 1999
- Privately owned
- 1500 sqm lab, based in Dortmund Germany (BioMedizinZentrum)
- 52 employees (> 50% Ph.D.)
- More than 6.000 projects delivered
- More than 200 customers served
- Invented "TarosGate ", the smart 24h/7 Project Management Software
- Taros is coordinating the Chemistry Consortium of the "European Lead Factory" drug discovery platform





What do we actually do





"A MAN'S WORTH IS NO GREATER THAN HIS AMBITIONS."

- MARCUS AURELIUS

"A PROJECTS WORTH IS NO GREATER THAN ITS AMBITIONS"




European Lead Factory Game Changing for Innovative Medicine

Dr Dimitrios Tzalis, ELF Coordinator for the Public Compound Collection

BMBF Kick-off Event IMI 2, 10th July 2014 Frankfurt



Collaborative Drug Discovery Plattform






The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115489, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.



Consortium with 30 Public and Private Partners



150 employees combining **innovation** of Academia, **agility** of SME's, and **experience** of Pharma





EUROPEAN LEAD FACTORY

www.europeanleadfactory.eu



The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115489, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.




















The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115489, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.






















SME: how to participate in an IMI call




2 Options

- create and coordinate a consortium
- join a consortium



















First problems to encounter:

Search: who fits into a potential consortium




















What is important when considering a new partner

- search should be INTERNATIONAL
- partner should be contributing proactive
- but first and foremost: the chemistry has to be right











SME: Grant Application

- follow exactly the call text
- close gaps that you have through partners
- if not sure clarify ahead of proposal submission





Do you need pre-existing experience in FP 7 to participate or coordinate an IMI Call?

• NO

but: IT REALLY HELPS

- there should be pre-existing experience with local and national funding agencies
- proper accounting and documentation procedures have to be in place



24



Do you need pre-existing experience with Big Pharma to participate or coordinate an IMI Call?

• NO

but: IT REALLY HELPS

- The goal of IMI calls is to generate VALUE by translating academic knowledge into commercial value (close in time and not some time in the future)
- Coordinator is a EFPIA representative





What about IP protection?



- IMI has laid out in the Grant Agreement clear rules and all builds on these
 - > Focus is that everybody has his/here IP/value protected
 - ➤ Fair treatment of all partners
 - >Exploitation of generated IP is a question of negotiation





Legal Issue: Project Agreement



- EFPIA and academia arrived with an "Armada" of highly experienced and competent lawyers
- essential in the application phase was a legal advisor (could be difficult for SMEs)
- we where 5 SME who shared costs for a legal advisor





Do you need external advisors supporting you with the IMI call?

YES!!!

- highly recommended: especially for SMEs
- highly experienced and provide infrastructure supporting the application-and project phase (reports, finance, formalities)
- normally free of charge during the application phase





How does IMI compare to "traditional" programms

- EFPIA is strongly involved
 - goal: generate value (value does not always mean €€)
 - intensive exchange with EFPIA in order to assure real application
- optimal utilization of:
 - -creativity of academia
 - -flexibility and agility of SMEs
 - -efficiency and vision of the "Big Pharma"
- it does not focus solemnly on the need of one partner but it is focused on one aspect:

The greater good of the patients and society



The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115489, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.



Things to look out for and be cautious









Benifits for SME in the participation in the IMI

- intensive exchange with EFPIA
- insite in requirements and operation of EFPIA partners and the needs of academic partners in the field of drug discovery
- partnerships and trust is being build
- loose cooperation on "equal" grounds
- access to a wide network of other SMEs, academic partners and big pharma representing potenially an entire Drug Discovery Value Chain




31



Lessons Learned







"TRY NOT TO BECOME A MAN OF SUCCESS, BUT RATHER TRY TO BECOME A MAN OF VALUE."

- ALBERT EINSTEIN



"Discovering The World Of Chemistry"

Dr. Dimitrios Tzalis

Taros Chemicals GmbH Co KG Emil Figge Str. 76a dtzalis@taros.de <u>www.taros.de</u> Tel +49 231 97427211

Thank you for your attentions

ANY QUESTIONS?

